Cannabis and Opioids: UCSF Study on Pain Relief

A University of California, San Francisco (UCSF) study¹ has found that combining cannabis with prescription opioids may offer greater pain relief than using opioids alone — even though the long-term effects of cannabis for pain remain unclear. The research, published in Clinical Pharmacology & Therapeutics in June 2022, suggests that integrated therapy could reduce opioid dosage requirements while improving patient comfort.

UCSF Study Overview: Cannabis and Opioid Interaction

The doctor-led study compared opioids — specifically sustained-release morphine or oxycodone — with cannabinoids, the bioactive compounds found in cannabis. Researchers also evaluated the effectiveness of combined therapy (opioids plus cannabinoids) for pain relief.

Lead author Dr. Donald Abrams, a professor of clinical medicine at UCSF, explained the motivation behind the research:

“Chronic pain is one of the problems we are least capable of managing.”

Chronic Pain in the U.S.: Scale and Impact

Pain is one of the primary reasons Americans seek medical treatment. According to the U.S. Centers for Disease Control and Prevention (CDC), roughly 50 million adults suffer from chronic pain — defined as pain persisting for three months or longer. This condition can severely diminish quality of life, impacting physical health, mental well-being, and daily function.

The economic toll is equally significant. Chronic pain is estimated to cost the U.S. economy around $80 billion annually in lost wages alone, not including medical expenses.

The Opioid Crisis Connection

For decades, opioids have been the standard treatment for moderate to severe chronic pain. While effective, they come with serious risks — including dependence, tolerance, and overdose. The ongoing opioid epidemic in the United States has claimed an estimated 500,000 lives over the past two decades due to overdoses.

One potential solution researchers are exploring is opioid-sparing therapy — combining opioids with other medications to reduce the required opioid dose while maintaining or improving pain control. Cannabis, with its unique mechanisms of action, has emerged as a candidate for this role.

How the Study Was Conducted

The UCSF study included 21 inpatient participants who were already receiving sustained-release morphine or oxycodone for chronic pain management. The participants were introduced to vaporized cannabis over a four-day period, during which their opioid use was withheld. Researchers then compared pain levels across different treatment approaches.

Results showed that patients receiving both cannabis and opioids reported greater pain relief than those receiving opioids alone. Importantly, the combination allowed for lower opioid dosages, which could help reduce dependence and mitigate overdose risk.

Key Findings: Cannabis Plus Opioid Therapy

The preliminary results suggest several key implications:

• Enhanced Pain Relief — Cannabis appears to boost the pain-relieving effects of opioids.
• Opioid Dose Reduction — Lower opioid requirements could reduce addiction potential and side effects.
• Possible Harm Reduction — By decreasing reliance on high-dose opioids, combined therapy could be part of broader strategies to combat the opioid crisis.

Dr. Abrams and his team believe this approach could help wean more patients off long-term opioid therapy while still effectively managing their pain.

Swipe to scroll →

Limitations and Need for Further Research

While promising, the study had a relatively small sample size and short treatment period. More extensive, randomized controlled trials are needed to confirm the results. Researchers also stressed the importance of studying different cannabis strains, cannabinoid profiles (THC vs. CBD ratios), and delivery methods to better understand which combinations are most effective and safe.

Additionally, the long-term effects of cannabis use for chronic pain remain insufficiently understood. Potential concerns include cognitive effects, dependency risk, and interactions with other medications.

The Bigger Picture

Cannabis is increasingly being considered as part of multimodal pain management — a strategy that uses multiple treatments to target different aspects of pain. In recent years, more U.S. states have legalized medical cannabis for chronic pain, and some clinical guidelines now suggest it as an adjunct option when standard treatments fall short.

However, barriers remain, including regulatory restrictions, variability in product quality, and lack of physician training in cannabinoid medicine. Education for healthcare providers will be critical if combined cannabis-opioid therapy is to become a viable mainstream treatment.

Conclusion

The UCSF study offers early evidence that combining cannabis with opioids may provide superior pain control compared to opioids alone — while potentially reducing opioid dosage requirements. If confirmed in larger, long-term studies, this approach could represent an important tool in both chronic pain management and opioid harm reduction.

For millions living with debilitating pain, this could mean not only better relief but also a lower risk of dependence, overdose, and diminished quality of life.

References:

^{1. Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E., & Benowitz, N. L. (2011). Cannabinoid–opioid interaction in chronic pain. Clinical Pharmacology & Therapeutics, 90(6), 844–851. https://doi.org/10.1038/clpt.2011.188}